Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Remission0–2
- Mild Disease3–5
- Moderate Disease6–10
- Severe Disease11–12
The Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis calculates assessing severity of ulcerative colitis using four clinical and endoscopic parameters. Key inputs include stool frequency. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Assesses severity of ulcerative colitis using four clinical and endoscopic parameters. Originally developed in 1987 to standardize assessment of ulcerative colitis activity and treatment response in clinical trials and practice. Widely used instrument for evaluating disease severity and monitoring therapeutic outcomes.
Clinical Indication
The Mayo Score/Disease Activity Index (DAI) for Ulcerative Colitis is indicated for bedside clinical practice to support Assesses severity of ulcerative colitis using four clinical and endoscopic parameters. Originally developed in 1987 to standardize assessment of ulcerative colitis activity and treatment response in clinical trials and practice. Widely used instrument for evaluating disease severity and monitoring therapeutic outcomes.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration. Clinical exclusion: Partial Mayo Score excludes endoscopic component (range 0-9 points).
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy. Guideline pearl: Widely used in FDA regulatory trials for ulcerative colitis treatments.
Mayo DAI Score = Stool Frequency points + Rectal Bleeding points + Mucosal Appearance points + Physician Global Assessment points. Maximum score 12 points.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| stool_frequency | string | Yes | Increase in stool frequency compared to patient's normal baseline. Assesses bowel movement frequency as indicator of disease activity and inflammation severity |
| rectal_bleeding | string | Yes | Presence and severity of rectal bleeding. Key indicator of mucosal inflammation and disease activity in ulcerative colitis |
| mucosal_appearance | string | Yes | Endoscopic findings of mucosal inflammation. Objective assessment of colonic mucosa appearance during endoscopy, critical for disease severity evaluation |
| physician_global_assessment | string | Yes | Physician's overall clinical assessment of disease activity. Incorporates clinical judgment considering all aspects of patient's condition including extraintestinal manifestations |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–2 | Remission | Disease remission |
| 3–5 | Mild Disease | Mildly active disease |
| 6–10 | Moderate Disease | Moderately active disease |
| 11–12 | Severe Disease | Severely active disease |
Evidence-Based References (EBM)
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9. doi: 10.1056/NEJM198712243172603.DOI: 10.1056/NEJM198712243172603
- D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007 Feb;132(2):763-86. doi: 10.1053/j.gastro.2006.12.038.DOI: 10.1053/j.gastro.2006.12.038
- Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008 Dec;14(12):1660-6. doi: 10.1002/ibd.20520.DOI: 10.1002/ibd.20520
- Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.DOI: 10.1056/NEJMoa1215734